制药公司开发新的减重药物,以保护肌肉,目标是到2030年实现1B-5B美元年度市场目标。 Pharma firms develop new weight-loss drugs to preserve muscle, targeting $1B-$5B annual market by 2030.

制药商正在开发新的减肥疗法，旨在保持肌肉质量，针对肌肉生长抑制素和激活素等蛋白质，以防止 Wegovy 和 Zepbound 等流行疗法中出现的肌肉衰退。 Drugmakers are developing new weight-loss treatments aimed at preserving muscle mass, targeting proteins like myostatin and activin to prevent muscle decline seen with popular treatments like Wegovy and Zepbound. 到本十年结束时,这些药物每年可能产生10亿至50亿美元。 These drugs could generate between $1 billion to $5 billion annually by the end of the decade. 林业发展局计划在试验中衡量肌肉对脂肪比率,以确保有效性,并可能考虑其他好处,例如改善心脏健康和减少批准决定的副作用。 The FDA plans to measure muscle-to-fat ratios in trials to ensure effectiveness and may consider additional benefits such as improved heart health and reduced side effects in approval decisions.